News
Fuel Tech Schedules 2022 Fourth Quarter and Full Year Financial Results and Conference Call
Fuel Tech, Inc. (NASDAQ: FTEK), a technology company providing advanced engineering solutions for the optimization of combustion systems, emissions control and water treatment in utility and
CI Financial Reports Financial Results for the Fourth Quarter of 2022
CI Financial Corp. (“CI”) (TSX: CIX) today released financial results for the quarter ended December 31, 2022.
“CI’s strong performance during an extended period of financial market volatility
EQS-News: Medios AG: Record revenue and earnings – Guidance 2022 achieved; further growth expected in financial year 2023
CI Global Asset Management Expands Suite of Covered Call Strategies with New ETF and Four Mutual Funds
CI Global Asset Management (“CI GAM”) announces the launch of a new series of covered call investment funds, including an ETF focused on the utilities sector. CI Utilities Giants Covered Call ETF
Lysogene Announces the Extension of Deadline for the Submission of Offers
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces that, upon decision of the judicial
Fujitec Co., Ltd.: Our Opinion on Glass Lewis’ Voting Recommendations on the Agenda Items to be Proposed at the Extraordinary General Meeting of Shareholders
Fujitec Co., Ltd. (TOKYO:6406):
As announced in the "Notice Concerning the Board of Directors' Position on the Agenda Item to be Submitted by the Company and the Agenda Items Proposed by a
OSE Immunotherapeutics Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies
Regulatory News:
OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) today provides a regulatory update on the clinical development plan of Tedopi®, an immunotherapy activating
GenSight Biologics Announces 1 Year Safety Data and Efficacy Signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa
Regulatory News:
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal
Fujitec Co., Ltd.: Our Opinion on Institutional Shareholder Services Inc.'s Voting Recommendations on the Agenda Items to be Proposed at the Extraordinary General Meeting of Shareholders
Fujitec Co., Ltd. (TOKYO:6406):
As announced in the “Notice Concerning the Board of Directors' Position on the Agenda Item to be Submitted by the Company and the Agenda Items Proposed by a
CI Global Asset Management Announces February 2023 Distributions for the CI ETFs
CI Global Asset Management (“CI GAM”) announces the following regular cash distributions for the month ending February 28, 2023 in respect of the CI ETFs. In all cases, the distribution will be
Fujitec Co., Ltd.: Additional Explanatory Material Regarding Our Position on the Extraordinary General Meeting of Shareholders
Fujitec Co., Ltd. (TOKYO:6406):
With regard to agenda items to be put forward at the Extraordinary General Meeting of the Shareholders, to be held February 24, 2023, and as described in the
CI Global Asset Management Builds on its Leadership in Alternative Investments with New Multi-Manager Private Markets Solution
CI Global Asset Management (“CI GAM”) announces a new investment solution designed to deliver the benefits of private markets investing to individual investors.
CI GAM is using a fund-of-funds
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
Vistagen (NASDAQ: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Fujitec Co., Ltd.: Notice Concerning the Board of Directors’ Position on the Agenda Item to be Submitted by the Company and Agenda Items Proposed by a Shareholder for the Upcoming Extraordinary General Meeting of the Shareholders
Fujitec Co., Ltd. (TOKYO:6406):
We disclosed in the “Notice Concerning a Shareholder’s Request for the Convocation of Extraordinary General Meeting of the Shareholders” dated December 6, 2022
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous
Granite REIT Announces Lease Extensions at its Properties in Graz, Austria
Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) announced today that the leases at its properties in Graz, Austria (the “Graz Facilities”), comprising approximately 5.0
CI Direct Investing Boosts Commitment to Straightforward Saving and Investing with Educational Collaboration
Online wealth management platform CI Direct Investing announces a collaboration with CacheFlo, a fintech specializing in behaviour-based education and tools, to help Canadians overcome the
CI Global Asset Management Investment Funds Honoured for Outstanding Performance
CI Global Asset Management (“CI GAM”) announces it has received 39 FundGrade A+® Awards for 2022. The winning CI GAM funds include 16 mutual funds and exchange-traded funds and 23 segregated funds
Lysogene: Conversion of the Safeguard Proceedings Into Reorganization Proceedings
Regulatory News:
Lysogene (FR0013233475 – LYS) (Paris:LYS), a phase 3 gene therapy platform Company targeting central nervous system (CNS) diseases, announces the conversion of the safeguard
Vistagen Announces First Participants Dosed in Phase 1 Clinical Trial of PH10, an Investigational Pherine Nasal Spray for Major Depressive Disorder
Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system
Granite REIT Declares Distribution for January 2023
Granite Real Estate Investment Trust (“Granite”) (TSX: GRT.UN / NYSE: GRP.U) announced today that its board of trustees has declared a distribution of CDN $0.2667 per stapled unit for the month of
CI Financial Reports Total Assets of $375.8 Billion for December 2022
CI Financial Corp. (“CI”) (TSX: CIX, NYSE: CIXX) today reported preliminary total assets of $375.8 billion as at December 31, 2022, consisting of asset management assets of $117.8 billion, Canadian
CI Global Asset Management Announces January 2023 Distributions for CI ETFs
CI Global Asset Management (“CI GAM”) announces the following regular cash distributions for the month ending January 31, 2023 in respect of the CI ETFs. In all cases, the distribution will be paid
CI Global Asset Management Announces Fund Merger, ETF Risk Rating Change
CI Global Asset Management (“CI GAM”) today announced a proposal to merge CI Global Equity Income Private Pool Class into CI Global Concentrated Equity Private Pool, and a risk rating change for